iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
Gene therapy is expanding into more diseases and treatment approaches, but it is not a single kind of treatment—and an FDA approval applies to a specific product and eligible population, not everyone with a related diagnosis. Recent U.S. approvals include therapies for inherited blood disorders, hearing loss and spinal muscular atrophy, while trial evidence, safety monitoring and postapproval confirmation remain central to how their benefits are assessed.
What gene therapy means
The U.S. Food and Drug Administration defines gene therapy as administering genetic material to modify or manipulate gene expression, or to alter the biological properties of living cells, for therapeutic use. FDA considers human CRISPR/Cas9 genome editing to be gene therapy.
That definition covers different methods. Some treatments use a viral vector, such as an adeno-associated virus (AAV), to deliver genetic material. Others modify a patient’s cells outside the body and return them as a cellular product. The delivery method, target, treatment process and risks can differ substantially; “gene therapy” alone does not tell a patient how a particular product works.
Do these 3 things before closing this tab:
1Clear out junk files and repair common Windows errors2Fix the driver behind crashes, sound loss and screen glitches3Repair Windows errors before they cause bigger problemsWhat has changed in the United States
Recent FDA actions show a broader range of diseases and approaches, alongside extensions of eligibility for an existing product. The examples below are not a head-to-head comparison: they involve different patient groups, study designs, endpoints and follow-up periods.
#1 Best Overall
| Product and FDA action | Who the action covers | What the evidence or pathway establishes |
|---|---|---|
| Itvisma (onasemnogene abeparvovec-brve), approved November 24, 2025 | Adults and children aged 2 years and older with spinal muscular atrophy (SMA) and a confirmed SMN1 mutation | FDA identifies Itvisma as AAV-based. The approval notice discusses hepatotoxicity and says most side effects are consistent with known Zolgensma risks. |
| Waskyra (etuvetidigene autotemcel), approved December 9, 2025 | Pediatric patients aged 6 months and older and adults with Wiskott-Aldrich syndrome who meet the label’s transplant and donor criteria | FDA describes two open-label studies and an expanded-access program totaling 27 patients. |
| Kresladi (marnetegragene autotemcel), approved March 26, 2026 | Pediatric patients with severe leukocyte adhesion deficiency type I (LAD-I) due to biallelic ITGB2 variants, when no HLA-matched sibling donor is available for allogeneic stem-cell transplant | FDA used accelerated approval, relying on biomarker increases with a sustained effect through month 24. |
| Otarmeni (lunsotogene parvec-cwha), approved April 23, 2026 | Pediatric and adult patients with severe-to-profound or profound hearing loss associated with biallelic OTOF variants | FDA granted accelerated approval based on one ongoing multicenter, single-arm trial. In the FDA notice, 80% of the 20 patients evaluable for efficacy experienced improved hearing. |
| Casgevy (exagamglogene autotemcel), supplemental approval July 1, 2026 | Patients aged 2 years and older with the specified forms of sickle cell disease or transfusion-dependent beta thalassemia covered by the expanded indication | FDA describes Casgevy as CRISPR-based. This was an expansion of eligibility, not a new product approval. |
The Otarmeni result is a finding in a defined group of 20 evaluable patients in one trial; it is not a guarantee of hearing improvement for an individual or proof of long-term benefit. FDA says continued approval may depend on confirming durability and effects on speech development and quality of life. Likewise, Kresladi’s accelerated approval was based on biomarker results, not a comparative efficacy ranking against the other products.
A 2026 review in Naunyn-Schmiedeberg’s Archives of Pharmacology counted four new cellular and gene therapy products approved by FDA in 2025. That is the review’s count, not an FDA year-by-year total, and it combines cellular and gene therapy products; it should not be read as a long-term growth rate.
Rank #2
Why an approval does not mean a general cure
Each approval is tied to a named product, indication, eligibility criteria, evidence package and regulatory pathway. For example, a diagnosis alone may not establish that someone meets a product’s age, genetic, disease-severity, donor or transplant criteria. The label and treating specialist’s assessment determine whether a particular product is relevant to a patient.
FDA’s catalog of cellular and gene therapy products is useful for seeing the range of regulated products, but it includes cellular therapies as well as gene therapies. A listing should not be taken to mean every cell therapy changes genetic material or uses the same mechanism.
How safety and follow-up differ by product
There is no single safety profile for gene therapy. Risks depend on the product and its delivery and treatment procedures. FDA’s Itvisma notice discusses hepatotoxicity. Its Otarmeni notice lists middle-ear infection, nausea, dizziness and procedural pain, and notes the need to monitor for surgical complications. Those examples should not be generalized to other therapies.
Follow-up is also part of interpreting an approval. With Otarmeni, FDA describes an ongoing single-arm study and the need to verify durable hearing improvement and assess clinical measures. With Kresladi, the approval notice describes a biomarker increase sustained through month 24. These are different kinds of evidence and do not by themselves establish identical or permanent outcomes.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What still has to improve
FDA guidance updated through 2026 addresses genome-editing safety assessment, clinical trial design for small populations, manufacturing controls and collection of postapproval safety and efficacy information. FDA also describes a lifecycle-oriented approach to some chemistry, manufacturing and controls requirements. These are important parts of development and oversight, but they do not by themselves establish how much manufacturing capacity exists, how quickly patients can access therapies or what treatment costs.
The Tool Desk
Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Small patient populations can make trial design and interpretation especially consequential: study design, chosen endpoint, length of follow-up and the obligation to confirm a benefit all shape what an approval establishes. Continued evidence collection is therefore part of the story, not a footnote to the approval announcement.
Best Value
Why DIY gene therapy is not a safe alternative
FDA warns against products intended for self-administration and do-it-yourself gene therapy kits. Its warning is direct: “The sale of these products is against the law. FDA is concerned about the safety risks involved.” A regulated therapy’s approval and monitoring do not make unapproved self-administered products safe; do not use or recommend DIY kits.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
